Global Artificial Pancreas Devices Systems Market Size Study, by Device Type (Threshold Suspend Device Systems, Control-to-Range Systems, Control-to-Target Systems), by End User (Hospitals, Clinics, Homecare), and Regional Forecasts 2022-2032

Global Artificial Pancreas Devices Systems Market is valued at approximately USD 289.9 Million in 2023 and is anticipated to grow with a healthy growth rate of 18.9% over the forecast period 2024-2032. Artificial pancreas device systems, often referred to as closed-loop insulin delivery systems, represent a transformative advancement in diabetes management. By seamlessly integrating continuous glucose monitors (CGMs), insulin pumps, and algorithm-driven automation, these devices dynamically adjust insulin delivery, mimicking the glucose-regulating functions of a healthy pancreas. This automation significantly reduces the burden of manual interventions and improves glycemic control, offering enhanced quality of life for individuals with type 1 diabetes.

The market is experiencing a surge in demand due to the escalating prevalence of diabetes worldwide, coupled with rapid technological advancements in wearable devices and predictive algorithms. For instance, in May 2024, the FDA approved the CamAPS FX system for use in pregnancy, highlighting the growing adoption of personalized and context-specific diabetes management solutions. Additionally, the integration of mobile applications and wearable technology is redefining patient engagement, enabling real-time monitoring and seamless remote connectivity, thereby fostering market growth.

While the high costs associated with these devices and concerns regarding data privacy pose challenges, increasing healthcare investments and favorable reimbursement policies are expected to mitigate these barriers. The continued focus on expanding access to advanced diabetes management solutions in emerging economies further underscores the market's potential for robust growth.

North America dominates the global market landscape, attributed to its well-established healthcare infrastructure, significant R&D investments, and the presence of major industry players. However, the Asia-Pacific region is anticipated to exhibit the fastest growth during the forecast period, driven by rising healthcare expenditure, large diabetic populations, and increasing awareness of digital health solutions.

Major market players included in this report are:

• Medtronic Plc
• Tandem Diabetes Care, Inc.
• Beta Bionics
• Bigfoot Biomedical, Inc.
• Insulet Corporation
• Diabeloop SA
• Johnson & Johnson
• Pancreum, Inc.
• TypeZero Technologies, LLC
• Roche Diabetes Care
• Abbott Laboratories
• Dexcom, Inc.
• Animas Corporation
• Inreda Diabetic
• EoFlow Co., Ltd.

The detailed segments and sub-segments of the market are explained below:

By Device Type:

• Threshold Suspend Device Systems
• Control-to-Range (CTR) Systems
• Control-to-Target (CTT) Systems

By End User:

• Hospitals
• Clinics
• Homecare

By Region:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA (Latin America, Middle East & Africa)
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Years considered for the study are as follows:

• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024-2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations for future market approaches.
• Demand-side and supply-side analysis of the market.